LPCN - Lipocine spikes after Phase 2 data for cirrhosis therapy
2023-07-27 13:46:53 ET
More on Lipocine
- Lipocine stock dips after bridging study data of LPCN 1154 for postpartum depression
- Lipocine announces plans to focus on treating CNS disorders, shares rise ~5%
- Lipocine announces FDA accepted the marketing application for Tlando
For further details see:
Lipocine spikes after Phase 2 data for cirrhosis therapy